Inclusion Criteria:

          -  Signed informed consent

          -  Age ≥ 18 years

          -  Histologically or cytologically confirmed advanced NSCLC (adenocarcinoma, squamous
             cell carcinoma, large cell carcinoma, undifferentiated carcinoma or other)

          -  Advanced NSCLC cancer patient with progressive disease after a first line of combo
             chemotherapy plus anti-PD-1 or chemotherapy plus anti-PD-L1 combination

          -  Measurable disease defined according to iRECIST v1.1 guidelines

          -  Patients must have a mandatory treatment-free interval of at least 21 days following
             previous systemic anti-cancer treatments

          -  Patients who have received previous systemic anticancer treatment and/or radiotherapy
             should have recovered from any treatment related toxicity, to a level of ≤ grade 1
             with the exception of Grade 2 alopecia

          -  Performance status 0 or 1 on the ECOG scale

          -  Females must be using highly effective contraceptive measures and have a negative
             pregnancy test prior to the start of dosing if of childbearing potential, or must have
             evidence of non-childbearing potential. Females of childbearing potential should use
             reliable methods of contraception from the time of the screening until 5 months after
             discontinuing study treatment. Male patients with a female partner of childbearing
             potential should be willing to use barrier contraception during the study and for 7
             months following discontinuation of study drug. Patients should refrain from donating
             sperm from the start of dosing until 7 months after discontinuing study treatment.

          -  Registration in a national health care system.

          -  Ability to comply with the study protocol, in the Investigator's judgment

        Exclusion Criteria:

          -  Diagnosis of additional malignancy within 2 years prior to the inclusion with the
             exception of curatively treated basal cell carcinoma of the skin and/or curatively
             resected in situ cervical or breast cancer

          -  Patient with any medical or psychiatric condition or disease, which would make the
             patient inappropriate for entry into this study

          -  Participation in a clinical study with an investigational product within 4 weeks prior
             to the start of the study treatment

          -  Patient under guardianship, curatorship or under the protection of justice

          -  Uncontrolled tumor-related pain

          -  Uncontrolled pleural effusion, pericardial effusion, ascites or symptomatic fistula

          -  Known active central nervous system metastases and/or carcinomatous meningitis

          -  Uncontrolled brain metastases

          -  Presence of EGFR mutation, ALK or ROS1 translocation

          -  history of hyperprogression during first line treatment with chemotherapy plus
             immunotherapy

          -  Inadequate organ functions: known cardiac failure of unstable coronaropathy,
             respiratory failure, or uncontrolled infection or another life-risk condition

          -  Active or chronic hepatitis B or C and/or HIV positive or known history of active
             Covid-19 infection, or a known history of active Tuberculosis bacillus

          -  Any immunosuppressive therapy (i.e. corticosteroids >10mg of hydrocortisone or
             equivalent dose) within 14 days before the planned start of study therapy

          -  Active autoimmune disease that has required a systemic treatment in past 2 years (i.e.
             corticosteroids or immunosuppressive drugs). Replacement therapy (e.g. thyroxine,
             insulin) is allowed

          -  Active or history of autoimmune disease or immune deficiency

          -  Prior allogeneic bone marrow transplantation or prior solid organ transplantation

          -  History of severe allergic, anaphylactic, or other hypersensitivity reactions to
             chimeric or humanized antibodies or fusion proteins

          -  Known hypersensitivity or allergy to Chinese hamster ovary cell products or any
             component of Nivolumab formulation

          -  History of idiopathic or secondary pulmonary fibrosis or evidence of active
             pneumonitis requiring a systemic treatment with 28 days before the planned start of
             study therapy

          -  Major surgical procedure other than for diagnosis within 4 weeks prior to initiation
             of study treatment, or anticipation of need for a major surgical procedure during the
             course of the study

          -  Severe infection within 4 weeks prior to initiation of study treatment, including, but
             not limited to, hospitalization for complications of infection, bacteremia, or severe
             pneumonia

          -  Treatment with therapeutic oral or IV antibiotics within 4 weeks prior to initiation
             of study treatment

          -  Receipt of a live, attenuated vaccine within 4 weeks prior to the initiation of
             treatment or anticipation that such a live, attenuated vaccine will be required during
             the study

          -  Patients requiring oxygen therapy

          -  For patients with a known cardiac history or with cardiac events occurring after
             first-line chemoimmunotherapy: LEVF<40% ; troponin > ULN; BNP > ULN

          -  Inadequate hematology, hepatic, renal functions or others inadequate laboratory values